PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis

PURPOSE: PIK3CA mutation is considered to be a possible cause for resistance to neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the association between PIK3CA mutations and the outcome of NAC in HER2-positive breast cancers. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Youjeong, Park, Yeon Hee, Ahn, Jin Seok, Im, Young-Hyuck, Nam, Seok Jin, Cho, Soo Youn, Cho, Eun Yoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310726/
https://www.ncbi.nlm.nih.gov/pubmed/30607159
http://dx.doi.org/10.4048/jbc.2018.21.e48

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310726/
https://www.ncbi.nlm.nih.gov/pubmed/30607159
http://dx.doi.org/10.4048/jbc.2018.21.e48

Ejemplares similares